Publications by authors named "N P Konstandin"

Article Synopsis
  • Acute megakaryoblastic leukaemia (AMKL) is a serious type of cancer that is hard to treat, and most patients don’t do well.
  • Scientists studied 38 adults with AMKL to learn more about their genes and how well different treatments worked.
  • Those who had a special transplant (called allo-HSCT) lived longer than those who only got regular treatment, but many still had a chance for the cancer to come back.
View Article and Find Full Text PDF

Background: Recently, molecular tumour boards (MTBs) have been integrated into the clinical routine. Since their benefit remains debated, we assessed MTB outcomes in the Comprehensive Cancer Center Ostbayern (CCCO) from 2019 to 2021.

Methods And Results: In total, 251 patients were included.

View Article and Find Full Text PDF
Article Synopsis
  • Scientists are studying a new treatment called WT1-TCB, which helps the immune system fight a type of cancer called acute myeloid leukemia (AML).
  • This new therapy works by targeting special proteins inside the cancer cells, making it easier to attack more types of leukemia.
  • In tests, WT1-TCB was very effective at killing AML cells, leading researchers to start a trial to see if it works for patients with tough cases of AML.
View Article and Find Full Text PDF

Previous studies demonstrated that splicing factor mutations are recurrent events in hematopoietic malignancies with both clinical and functional implications. However, their aberrant splicing patterns in acute myeloid leukemia remain largely unexplored. In this study, we characterized mutations in SRSF2, U2AF1, and SF3B1, the most commonly mutated splicing factors.

View Article and Find Full Text PDF

The revised 2017 European LeukemiaNet (ELN) recommendations for genetic risk stratification of acute myeloid leukemia have been widely adopted, but have not yet been validated in large cohorts of AML patients. We studied 1116 newly diagnosed AML patients (age range, 18-86 years) who had received induction chemotherapy. Among 771 patients not selected by genetics, the ELN-2017 classification re-assigned 26.

View Article and Find Full Text PDF